Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/08/2022 | Q2 2022 | -$1.18 | -$1.26 | -0.08 | N/A | $71.55 M |
05/04/2022 | Q1 2022 | -$1.30 | -$1.26 | 0.04 | N/A | $55.16 M |
02/23/2022 | Q4 2021 | -$1.13 | -$1.42 | -0.29 | N/A | $56.10 M |
11/04/2021 | Q3 2021 | -$1.11 | -$1.13 | -0.02 | N/A | $52.05 M |
08/03/2021 | Q2 2021 | -$1.19 | -$1.12 | 0.07 | N/A | $47.56 M |
05/05/2021 | Q1 2021 | -$1.01 | -$1.21 | -0.2 | N/A | $39.04 M |
02/24/2021 | Q4 2020 | -$0.94 | -$1.00 | -0.06 | N/A | $41.30 M |
11/05/2020 | Q3 2020 | -$0.76 | -$0.97 | -0.21 | N/A | $36.89 M |
08/05/2020 | Q2 2020 | -$1.15 | -$0.86 | 0.29 | N/A | $31.50 M |
05/06/2020 | Q1 2020 | -$1.51 | -$1.20 | 0.31 | N/A | $14.12 M |
02/26/2020 | Q4 2019 | -$1.24 | -$1.59 | -0.35 | N/A | $2.11 M |
11/07/2019 | Q3 2019 | -$1.05 | -$1.07 | -0.02 | N/A | $0 |
08/07/2019 | Q2 2019 | -$0.96 | -$1.01 | -0.05 | N/A | $0 |
05/09/2019 | Q1 2019 | N/A | -$0.87 | N/A | N/A | $0 |
02/27/2019 | Q4 2018 | -$0.89 | -$0.93 | -0.04 | N/A | $0 |
11/06/2018 | Q3 2018 | -$0.86 | -$0.83 | 0.03 | N/A | $0 |
08/02/2018 | Q2 2018 | -$0.88 | -$0.78 | 0.1 | N/A | $0 |
05/07/2018 | Q1 2018 | -$0.91 | -$0.87 | 0.04 | N/A | $0 |
02/27/2018 | Q4 2017 | -$0.71 | -$0.94 | -0.23 | N/A | $0 |
11/02/2017 | Q3 2017 | -$0.61 | -$0.66 | -0.05 | N/A | $0 |
Global Blood Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based offlast year's report dates.
The conference call for Global Blood Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Global Blood Therapeutics, Inc.'s latest earnings report can be read online.
Global Blood Therapeutics, Inc. (:GBT) has a recorded annual revenue of $194.75 M.
Global Blood Therapeutics, Inc. (:GBT) has a recorded net income of $-303,091,000.Global Blood Therapeutics, Inc. has generated $-4.82 earnings per share over the last four quarters.
Global Blood Therapeutics, Inc. (:GBT) has a price-to-earnings ratio of -14.22 and price/earnings-to-growth ratio is -0.14.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED